TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9863110

Group type: EXPERIMENTAL
Intervention: Xiaoliu Tablet (XLT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal women
Number of subjects: 71
Study: 8306925

Group type: EXPERIMENTAL
Intervention: haloperidol (40 mg a day) + carbamazepine (400 mg a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: haloperidol (40 mg a day) + bromocriptine (2.5 mg a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: haloperidol (40 mg a day) + cyproheptadine (24 mg a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: haloperidol (40 mg a day) + placebo
Number of subjects: 24
Study: 3521475

Group type: EXPERIMENTAL
Intervention: Azlocillin plus amikacin
Number of subjects: 742

Group type: COMPARATOR
Intervention: Cefotaxime plus amikacin
Number of subjects: 742

Group type: COMPARATOR
Intervention: Ticarcillin plus amikacin
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Patients with gram-negative rod bacteremias and profound granulocytopenia
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Patients with rising granulocyte counts
Number of subjects: 742
Study: 30146495

Group type: EXPERIMENTAL
Intervention: Aripiprazole (5 mg uncoated tablets)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg uncoated tablets)
Number of subjects: 30
Study: 26988025

Group type: EXPERIMENTAL
Intervention: Zirconia abutments
Number of subjects: 56

Group type: COMPARATOR
Intervention: Titanium abutments
Number of subjects: 56

Group type: COMPARATOR
Intervention: Titanium nitride abutments
Number of subjects: 56
Study: 24387003

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48 IU)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22281801

Group type: EXPERIMENTAL
Intervention: Auto-servoventilation (ASV)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both ASV and CPAP
Number of subjects: 70
Study: 20369701

Group type: EXPERIMENTAL
Intervention: Spermatic vein and artery ligation (n = 46)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Spermatic vein and artery preservation (n = 42)
Number of subjects: 88
Study: 18491670

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement (RMGIC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Polyacid‐modified resin composite (PMC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High viscosity GIC (HVGIC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amalgam (Amlg)
Number of subjects: 45
Study: 15941800

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (300 mg/d for 6 months)
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Clinic enrollment
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Clinic enrollment (excluding individuals with a history of tuberculosis)
Number of subjects: 1655
Study: 12638100

Group type: EXPERIMENTAL
Intervention: Heatwrap therapy
Number of subjects: 76
Study: 10842858

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 28

Group type: COMPARATOR
Intervention: Noninfected control subjects
Number of subjects: 28
Study: 8983316

Group type: EXPERIMENTAL
Intervention: Diclofenac resinate 75mg taken once or twice daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional enteric‐coated diclofenac sodium 50mg tablets given two or three times daily
Number of subjects: 216
Study: 1931143

Group type: EXPERIMENTAL
Intervention: Active aspirin and active beta-carotene
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Active aspirin and beta-carotene placebo
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Aspirin placebo and active beta-carotene
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 22071
Study: 7180622

Group type: EXPERIMENTAL
Intervention: 6, 12 or 24 hours of sensory deprivation
Number of subjects: 72

Group type: COMPARATOR
Intervention: 24 hours of social isolation
Number of subjects: 72
Study: 30569416

Group type: EXPERIMENTAL
Intervention: Laser helmet (RAMACAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham helmet
Number of subjects: 40
Study: 28183702

Group type: EXPERIMENTAL
Intervention: Individuals with diabetes mellitus (HbA1c levels)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Individuals without diabetes mellitus (HbA1c levels)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Total study population (HbA1c levels)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Highest HbA1c tertile
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Individuals without self-reported diabetes mellitus
Number of subjects: 319
Study: 25801942

Group type: EXPERIMENTAL
Intervention: Ethanol (doses: 6, 12, 18, 24, 30, and 42 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 24
Study: 23688259

Group type: EXPERIMENTAL
Intervention: Antenatal dietary and physical activity counselling
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 185
Study: 21385352

Group type: EXPERIMENTAL
Intervention: Ward-based pharmacy care from the clinical pharmacy team, including medication reconciliation at admission, daily medication review, and patient counselling at discharge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ward-based pharmacy care.
Number of subjects: 0
Study: 19107948

Group type: EXPERIMENTAL
Intervention: Submandibular salivary gland transfer (SGT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 120
Study: 17405999

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12684305

Group type: EXPERIMENTAL
Intervention: Blood cultures (BCs) performed
Number of subjects: 760
Study: 10888712

Group type: EXPERIMENTAL
Intervention: leflunomide (loading dose 100 mg/day for 3 days, maintenance dose 20 mg/day)
Number of subjects: 999

Group type: COMPARATOR
Intervention: methotrexate (10-15 mg/week)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 999

Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 999
Study: 9365968

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 50
Study: 1526090

Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (150 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (200 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (50, 100, 150, 200 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ro 40‐5967
Number of subjects: 64
Study: 3549681

Group type: EXPERIMENTAL
Intervention: Imipramine (3 mg/kg/day)
Number of subjects: 10
Study: 29958042

Group type: EXPERIMENTAL
Intervention: Methadone referral
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Buprenorphine referral
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 959
Study: 26227577

Group type: EXPERIMENTAL
Intervention: Partners for Change Outcome Management System (PCOMS) feedback scales
Number of subjects: 75

Group type: COMPARATOR
Intervention: Treatment as usual (no feedback scales)
Number of subjects: 75
Study: 24030518

Group type: EXPERIMENTAL
Intervention: 10g gel-forming pectin
Number of subjects: 32

Group type: COMPARATOR
Intervention: 3g gelatin and 2g starch (control)
Number of subjects: 32
Study: 23160228

Group type: EXPERIMENTAL
Intervention: SYSADOA group chemicals administered orally for 13 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 34
Study: 20560030

Group type: EXPERIMENTAL
Intervention: Intramyocardial BMMC injection
Number of subjects: 109

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 109
Study: 18630763

Group type: EXPERIMENTAL
Intervention: I.M ketoprofen (100 mg) + interpleural bupivacaine (0.4 ml/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: I.M pethidine (1.5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: I.M ketoprofen (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: interpleural bupivacaine (0.4 ml/kg)
Number of subjects: 40
Study: 15714901

Group type: EXPERIMENTAL
Intervention: Alcoholics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 11834852

Group type: EXPERIMENTAL
Intervention: Intralesional 2.5 mg/ml verapamil hydrochloride injections administered at timed intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving the same treatment except the verapamil hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intralesional 2.5 mg/ml verapamil hydrochloride injections
Number of subjects: 0
Study: 10573445

Group type: EXPERIMENTAL
Intervention: Positive stereotype reinforcement
Number of subjects: 47

Group type: COMPARATOR
Intervention: Negative stereotype reinforcement
Number of subjects: 47
Study: 8918275

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 19185

Group type: COMPARATOR
Intervention: Aspirin (325 mg once daily)
Number of subjects: 19185

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 19185

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 19185
Study: 2031046

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (5 mg inhaled 3 times daily) with PEP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (5 mg inhaled 3 times daily) without PEP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo inhalations with PEP
Number of subjects: 10
Study: 7216603

Group type: EXPERIMENTAL
Intervention: Exercise (2 h/d on a bicycle ergometer)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No exercise (control condition)
Number of subjects: 3
Study: 30321947

Group type: EXPERIMENTAL
Intervention: Vitamin C 500mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablet twice a day
Number of subjects: 0
Study: 28272250

Group type: EXPERIMENTAL
Intervention: Oxycodone IV-PCA (7.5 mg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Fentanyl IV-PCA (100 μg)
Number of subjects: 127
Study: 26433318

Group type: EXPERIMENTAL
Intervention: Tight control (review every 4 weeks, escalation of treatment if minimal disease activity criteria not met)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care (standard therapy according to the treating clinician, review every 12 weeks)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 206
Study: 24158181

Group type: EXPERIMENTAL
Intervention: Attending biosketch card intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no biosketch card)
Number of subjects: 212
Study: 22524296

Group type: EXPERIMENTAL
Intervention: High-value associations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-value associations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reward-related activation changes in dentate gyrus/CA(2,3) during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional connectivity between dentate gyrus/CA(2,3) and dopaminergic midbrain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-value associations during retrieval
Number of subjects: 0
Study: 19464025

Group type: EXPERIMENTAL
Intervention: Offer pacifier
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Not offer pacifier
Number of subjects: 1021
Study: 17767451

Group type: EXPERIMENTAL
Intervention: CathRite system
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (standard 'blind' technique)
Number of subjects: 38
Study: 15084178

Group type: EXPERIMENTAL
Intervention: Daclizumab group (1 mg/kg daclizumab and 100 mg prednisolone for 3 days)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control group (steroids tapered to 0 mg at week 16)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Daclizumab group
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 364
Study: 11165423

Group type: EXPERIMENTAL
Intervention: Low-Dose Oral Alpha Interferon
Number of subjects: 0
Study: 9884853

Group type: EXPERIMENTAL
Intervention: Tropisetron (2 mg)
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 842
Study: 8004831

Group type: EXPERIMENTAL
Intervention: Fish oil treatment for two years
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Hypertension management with enalapril maleate
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 106
Study: 2680186

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 380483

Group type: EXPERIMENTAL
Intervention: 20 micron microaggregate filter
Number of subjects: 40

Group type: COMPARATOR
Intervention: 260 micron standard filter
Number of subjects: 40
Study: 30225992

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28351782

Group type: EXPERIMENTAL
Intervention: FP/FOR (1000/40 μg)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: FP/FOR (500/20 μg)
Number of subjects: 225

Group type: COMPARATOR
Intervention: FP/SAL (1000/100 μg)
Number of subjects: 225

Group type: COMPARATOR
Intervention: 1 to 2 exacerbations in 12 months before phase 1
Number of subjects: 225
Study: 26436207

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (four 5-minute inflations and deflations of a standard blood-pressure cuff on the upper arm)
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Sham conditioning (control group)
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Remote ischemic preconditioning and Sham conditioning (control group)
Number of subjects: 1612
Study: 24228894

Group type: EXPERIMENTAL
Intervention: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy, titrated to 60 mg/day at week 6 if blood pressure exceeded 140/90 mmHg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 21129756

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: IVIG (2 g/kg)
Number of subjects: 106
Study: 19726593

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150 microg I daily for 28 weeks)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 17879366

Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg oral doses every 8 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Telaprevir and peginterferon alfa-2a (telaprevir 750 mg every 8 hours and peginterferon alfa-2a 180 mug weekly subcutaneous injections)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo and peginterferon alfa-2a
Number of subjects: 20
Study: 16890357

Group type: EXPERIMENTAL
Intervention: Treatment group (n=24) underwent conditioning with anaesthetic cream on one arm, followed by evaluation of pain intensity ratings.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n=16) did not receive the conditioning treatment.
Number of subjects: 40
Study: 14656614

Group type: EXPERIMENTAL
Intervention: Educational self-management intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 10513866

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MP) 125 mg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MP)
Number of subjects: 20
Study: 7500368

Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy for Couples (EFT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Inhibited sexual desire (ISD) couples
Number of subjects: 49
Study: 1742400

Group type: EXPERIMENTAL
Intervention: r-IFN (3 MU subcutaneously three times a week for 24 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: r-IFN
Number of subjects: 30
Study: 7179188

Group type: EXPERIMENTAL
Intervention: Autologous irradiated tumour cells and BCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single preoperative injection of BCG
Number of subjects: 0
Study: 31594253

Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 352
Study: 28922784

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 19,541), goal of reducing total fat intake and increasing intake of vegetables, fruits, and grains.
Number of subjects: 48235

Group type: COMPARATOR
Intervention: Usual diet comparison group (n = 29,294).
Number of subjects: 48235

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention among women with BMI ≥ 25 kg/m2.
Number of subjects: 48235

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention among women with BMI < 25 kg/m2.
Number of subjects: 48235
Study: 26189647

Group type: EXPERIMENTAL
Intervention: Selective head cooling (SHC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Whole-body cooling (WBC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Composite outcome of death or severe disability
Number of subjects: 29
Study: 25014766

Group type: EXPERIMENTAL
Intervention: Conventional blood pressure measurement
Number of subjects: 170
Study: 22955309

Group type: COMPARATOR
Intervention: End-to-end repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overlapping repair
Number of subjects: 0
Study: 20594464

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 303
Study: 18358883

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80
Study: 16094219

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate‐impregnated sponge dressing (Biopatch) covered by a transparent polyurethane dressing
Number of subjects: 145

Group type: COMPARATOR
Intervention: Transparent polyurethane insertion site dressing (control group)
Number of subjects: 145
Study: 11818701

Group type: EXPERIMENTAL
Intervention: Lisinopril (up to 20 mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (up to 90 mg/day)
Number of subjects: 32
Study: 10369095

Group type: EXPERIMENTAL
Intervention: Left hemisphere lesions in females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hemisphere lesions in females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hemisphere lesions in males
Number of subjects: 0

Group type: COMPARATOR
Intervention: Left hemisphere lesions in males
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (males)
Number of subjects: 0
Study: 7474192

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2189997

Group type: EXPERIMENTAL
Intervention: Experimental paradigm for studying illness cognition and behavior
Number of subjects: 0
Study: 7007668

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (14 students)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (19 students)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (12 students)
Number of subjects: 45
Study: 31820309

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 5-year incidence of T2D
Number of subjects: 32766
Study: 31594555

Group type: EXPERIMENTAL
Intervention: AMBER care bundle
Number of subjects: 65
Study: 29126212

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day for 9 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 26496098

Group type: EXPERIMENTAL
Intervention: 2-L Lactated Ringer's (LR)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 2-L Normal Saline (NS)
Number of subjects: 157

Group type: COMPARATOR
Intervention: No intravenous fluid (noIVF)
Number of subjects: 157
Study: 24045789

Group type: EXPERIMENTAL
Intervention: Late-evening snack (LES) containing 200 kcal (50 g CHO)
Number of subjects: 70
Study: 21320319

Group type: EXPERIMENTAL
Intervention: Decision aid group (n = 100)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care group (n = 70)
Number of subjects: 170
Study: 19050053

Group type: EXPERIMENTAL
Intervention: GIP + 10 mg sulfonylurea (SU, glipizide)
Number of subjects: 12

Group type: COMPARATOR
Intervention: GIP
Number of subjects: 12
Study: 16702497

Group type: EXPERIMENTAL
Intervention: Adapalene gel, 0.1%
Number of subjects: 253

Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 253
Study: 14570790

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laryngeal Tube (LT)
Number of subjects: 32
Study: 10776690

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 3 mg/kg per day
Number of subjects: 103

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 0.15 mg/kg per week
Number of subjects: 103
Study: 8624184

Group type: EXPERIMENTAL
Intervention: Voucher-based reinforcement for cocaine-free urine samples (3 times per week for 12 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Noncontingent vouchers
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Voucher-based reinforcement for cocaine-free urine samples
Number of subjects: 37
Study: 1300623

Group type: EXPERIMENTAL
Intervention: Dietary and/or drug intervention
Number of subjects: 675
Study: 6542243

Group type: EXPERIMENTAL
Intervention: Cis-platinum at 8 mg/m2 with 4 l of i.v. hydration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cis-platinum at 6 mg/m2 without i.v. hydration
Number of subjects: 21
Study: 30243958

Group type: EXPERIMENTAL
Intervention: Acute stress task (Trier Social Stress Test)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-stress task
Number of subjects: 80